Corrigendum to ‘Tumor cavitation at durvalumab initiation predicts poor survival in stage III NSCLC after concurrent chemoradiotherapy: A single-center retrospective cohort study’ [Respir Investig 64/5 (2026) 101503]
Corrigendum to ‘Tumor cavitation at durvalumab initiation predicts poor survival in stage III NSCLC after concurrent chemoradiotherapy: A single-center retrospective cohort study’ [Respir Investig 64/5 (2026) 101503]. // Respiratory Investigation. – URL: https://www.sciencedirect.com/science/article/pii/S2212534526001516?dgcid=rss_sd_all
Corrigendum to ‘Tumor cavitation at durvalumab initiation predicts poor survival in stage III NSCLC after concurrent chemoradiotherapy: A single-center retrospective cohort study’ [Respir Investig 64/5 (2026) 101503]. Respiratory Investigation. https://www.sciencedirect.com/science/article/pii/S2212534526001516?dgcid=rss_sd_all
“Corrigendum to ‘Tumor cavitation at durvalumab initiation predicts poor survival in stage III NSCLC after concurrent chemoradiotherapy: A single-center retrospective cohort study’ [Respir Investig 64/5 (2026) 101503].” Respiratory Investigation.
@article{article64392,
title = {Corrigendum to ‘Tumor cavitation at durvalumab initiation predicts poor survival in stage III NSCLC after concurrent chemoradiotherapy: A single-center retrospective cohort study’ [Respir Investig 64/5 (2026) 101503]},
journal = {Respiratory Investigation},
url = {https://www.sciencedirect.com/science/article/pii/S2212534526001516?dgcid=rss_sd_all}
}